- Home
- NMCO vs CRMD Comparison
NMCO vs CRMD Comparison
Compare NMCO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | CRMD |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.0M | 876.7M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NMCO | CRMD |
|---|---|---|
| Price | $10.50 | $11.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 207.6K | ★ 2.9M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | N/A | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | ★ N/A | $5.10 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $8.52 | $5.60 |
| 52 Week High | $11.64 | $17.43 |
Technical Indicators
Market Signals| Indicator | NMCO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 58.75 |
| Support Level | $10.60 | $10.90 |
| Resistance Level | $10.78 | $11.92 |
| Average True Range (ATR) | 0.11 | 0.51 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 15.63 | 76.86 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.